HMG (human menopausal gonadotropin, or menotropin) is a prescription fertility medication. This page describes its recognized reproductive roles, not wellness or performance claims.
The short answer
HMG's benefit is fertility, and specifically the growth of ovarian follicles. Its defining property is that a single preparation supplies both follicle-stimulating hormone activity and luteinizing hormone activity, where recombinant products supply one or the other. Whether that combination is actually better has been studied directly, and the answer is more interesting than "yes" or "no": highly purified menotropins produce fewer oocytes than recombinant FSH while achieving comparable pregnancy rates.
Everything HMG does is reproductive. It has no wellness, performance, or metabolic indication, and its risks — which are substantial — are the risks of driving ovaries harder than they would go on their own.
What the label covers
The Menopur label carries a single approved indication: development of multiple follicles and pregnancy in ovulatory women as part of an assisted reproductive technology cycle (Menopur label, DailyMed). The initial U.S. approval date on that label is 1975 — menotropins are one of the older products in this reference, not a novel compound.
The label also front-loads a diagnostic workflow before any dosing: a complete gynecologic and endocrinologic evaluation with the cause of infertility diagnosed, pregnancy excluded, the male partner's fertility status evaluated, and primary ovarian failure excluded. That last exclusion is the mechanistic boundary — gonadotropins instruct ovaries, so ovaries that cannot respond will not.
A profile review of the product describes the wider clinical use, including ovulation induction in anovulatory infertility, and notes that HMG carries a different endocrine signature from recombinant FSH in terms of serum FSH, androgen, and estradiol levels (PMID 30264288).
HMG versus recombinant FSH
This is the comparison that matters clinically, and the published profile summarizes it as follows (PMID 30264288):
- Pregnancy rates in IVF/ICSI: Menopur was as good as recombinant FSH for controlled ovarian stimulation — despite being associated with a lower oocyte yield.
- Embryo quality: some aspects improved in the IVF setting, though not in ICSI.
- Combination: using Menopur together with highly purified urinary FSH produced reproductive outcomes similar to Menopur alone.
- Ovulation induction: data are limited, but ovulation rates appear comparable to rFSH plus rLH in type 1 anovulation and to rFSH in type 2.
- Ovarian response: compared with recombinant FSH, Menopur appeared to produce a less pronounced follicular response and a lower risk of ovarian overstimulation.
The pairing of the first and last bullets is the substantive finding. Fewer eggs and equal pregnancies means oocyte count is not the outcome patients are actually buying, and a gentler follicular response is a safety asset rather than a shortfall — given that overstimulation is the primary hazard of this entire drug class.
The male-fertility context
HMG's FSH activity is also used off-label in men with gonadotropin deficiency, paired with hCG supplying the LH-like signal. The quantitative case for adding an FSH source is strong: across 41 studies and 1,673 men with pathological gonadotropin deficiency, combined hCG plus FSH outperformed hCG monotherapy on mean sperm output and on every sperm concentration threshold measured — even though testosterone and testicular volume rose similarly on both (PMID 39445789).
That dissociation is informative. Testosterone and testicular size are poor proxies for the outcome men in this situation want; the FSH arm is what moves sperm production.
What the benefits do not extend to
Menopur's label is Pregnancy Category X, and safety and efficacy have not been established in pediatric patients or characterized in renal or hepatic insufficiency. Nothing in the evidence base speaks to general hormone optimization, and there is no context in which "supporting fertility" and "wellness supplementation" mean the same thing here — this is a drug that recruits multiple follicles simultaneously, which is exactly why the side-effects page is dominated by ovarian hyperstimulation syndrome and multi-fetal gestation.